We conducted a systematic review to summarise the current clinical trial data examining angiogenesis inhibitors in HNSCC.<h4>Methods</h4>We carried out a literature search on three angiogenesis inhibitor categories-bevacizumab, tyrosine kinase inhibitors and endostatin-from Ovid MEDLINE, Cochrane Library, Scopus and ClinicalTrials.gov database.<h4>Results</h4>Here, we analysed 38 clinical trials, total of 1670 patients, investigating 12 angiogenesis inhibitors. The gene discussed is COL18A1; the disease is head and neck squamous cell carcinoma.